Highlights Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-08 pm EDT			5-day change	1st Jan Change
4.88 ^USD	-2.89%		-9.80%	-21.92%

Jun. 12	Transcript : Affimed N.V., Q1 2024 Earnings Call, Jun 12, 2024
Jun. 12	Affimed N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Affimed N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	Jun. 12	CI
Affimed N.V. Provides Follow-Up Data of AFM24 Plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-Type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort	Jun. 01	CI
Affimed N.V. Receives Fast Track Designation for Combination Therapy of Afm24 with Atezolizumab for Egfr Wild-Type Non-Small Cell Lung Cancer	May. 29	CI
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024	May. 23	CI
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer	Jan. 08	CI
Affimed to Sell AbCheck to Ampersand Biomedicines for $6 Million in Cash, Stock; Shares Fall	Jan. 03	MT
Ampersand Biomedicines Inc. entered into a definitive agreement to acquire AbCheck s.r.o. from Affimed N.V. for $6.4 million.	Jan. 02	CI
Affimed N.V. Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-Treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients	Dec. 11	CI
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic Nk in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (Bv) and Checkpoint Inhibitors	Dec. 11	CI
Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Affimed N.V. Presents Preclinical Data Showing That Addition of an Innate Cell Engager to Nk and Car-Nk Cells	Nov. 03	CI
Affimed N.V. Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting	Nov. 02	CI
Affimed to Transfer Listing to Nasdaq Capital Market	23-10-04	MT
Looming Inflation Report Drags Exchange-Traded Funds, Equity Futures Lower Premarket Tuesday	23-09-12	MT
Affimed Says FDA Granted Fast Track Designation to Combination Therapy to Treat Hodgkin Lymphoma	23-09-12	MT
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK(R) for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma	23-09-12	CI
Affimed N.V. Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability	23-08-22	CI
Affimed N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Highlights

Filters